Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · IEX Real-Time Price · USD
129.86
+5.41 (4.35%)
At close: May 31, 2024, 4:00 PM
130.25
+0.39 (0.30%)
After-hours: May 31, 2024, 7:53 PM EDT
Sarepta Therapeutics Employees
Sarepta Therapeutics had 1,314 employees on December 31, 2023. The number of employees increased by 152 or 13.08% compared to the previous year.
Employees
1,314
Change (1Y)
152
Growth (1Y)
13.08%
Revenue / Employee
$1,067,960
Profits / Employee
$12,859
Market Cap
12.27B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,314 | 152 | 13.08% |
Dec 31, 2022 | 1,162 | 322 | 38.33% |
Dec 31, 2021 | 840 | -26 | -3.00% |
Dec 31, 2020 | 866 | 123 | 16.55% |
Dec 31, 2019 | 743 | 244 | 48.90% |
Dec 31, 2018 | 499 | 244 | 95.69% |
Dec 31, 2017 | 255 | 58 | 29.44% |
Dec 31, 2016 | 197 | -73 | -27.04% |
Dec 31, 2015 | 270 | 66 | 32.35% |
Dec 31, 2014 | 204 | 58 | 39.73% |
Dec 31, 2013 | 146 | 43 | 41.75% |
Dec 31, 2012 | 103 | 5 | 5.10% |
Dec 31, 2011 | 98 | 0 | - |
Dec 31, 2010 | 98 | 35 | 55.56% |
Dec 31, 2009 | 63 | -20 | -24.10% |
Dec 31, 2008 | 83 | -42 | -33.60% |
Dec 31, 2007 | 125 | 8 | 6.84% |
Dec 31, 2006 | 117 | -6 | -4.88% |
Dec 31, 2005 | 123 | 11 | 9.82% |
Dec 31, 2004 | 112 | 6 | 5.66% |
Dec 31, 2003 | 106 | 17 | 19.10% |
Dec 31, 2002 | 89 | 4 | 4.71% |
Dec 31, 2001 | 85 | 14 | 19.72% |
Dec 31, 2000 | 71 | 15 | 26.79% |
Dec 31, 1999 | 56 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Fresenius Medical Care AG & Co. KGaA | 119,845 |
Universal Health Services | 96,700 |
Viatris | 38,000 |
Dr. Reddy's Laboratories | 25,863 |
Medpace Holdings | 5,900 |
Bio-Techne | 3,050 |
Insulet | 3,000 |
ShockWave Medical | 1,468 |
SRPT News
- 1 day ago - Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 days ago - Sarepta Therapeutics stock to enter S&P MidCap 400: Should you buy? - Invezz
- 4 weeks ago - Gene Therapy Pioneer Jerry R. Mendell, M.D. - Business Wire
- 4 weeks ago - Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments - Business Wire
- 5 weeks ago - Sarepta Therapeutics to Announce First Quarter 2024 Financial Results - Business Wire
- 2 months ago - Outperforming ETF manager names a potential ‘50-bagger' in the stock market - Market Watch
- 3 months ago - Sarepta Therapeutics to Present at Upcoming Investor Conferences - Business Wire
- 3 months ago - Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program - Business Wire